title: The usefulness of a cholesterol absorption inhibitor in Japanese type 2 diabetes patients with dyslipidemia.
abstract: OBJECTIVE
  Cholesterol absorption has been suggested to be an independent risk factor for cerebral and cardiovascular events. We studied the clinical efficacy of ezetimibe in Japanese patients with type 2 diabetes mellitus complicated by dyslipidemia, in whom increased cholesterol absorption had been reported.
  
  
  METHODS
  Ninety-six patients with type 2 diabetes complicated by dyslipidemia received ezetimibe at 10 mg/day for 12 weeks. The lipid profile, a cholesterol synthesis marker (lathosterol), and cholesterol absorption markers (cholestanol, sitosterol, and campesterol) were measured before and after the therapy to evaluate the clinical efficacy of ezetimibe.
  
  
  RESULTS
  Serum low-density lipoprotein-cholesterol (LDL-C) levels were positively associated with cholesterol absorption markers but not associated with a cholesterol synthesis marker, suggesting that serum LDL-C levels are more strongly related to cholesterol absorption than synthesis. During the 12-week ezetimibe treatment period, cholesterol absorption markers significantly decreased, and serum lipid profiles, including LDL-C levels, significantly improved. The LDL-C-lowering rate was greater in those patients who had been receiving statin therapy and were newly started on ezetimibe additionally than in the ezetimibe monotherapy group (-31.4% vs. -18.4%; P<0.001).
  
  
  CONCLUSIONS
  It is suggested that ezetimibe improves the lipid profile in Japanese type 2 diabetes patients with dyslipidemia through the substantial reduction of cholesterol absorption.
authors.affiliation: 1 Osaka Police Hospital , Osaka, Japan .
authors.forename: Takashi
authors.initials: T
authors.lastname: Katsura
authors.forename: Naoto
authors.initials: N
authors.lastname: Katakami
authors.forename: Yoko
authors.initials: Y
authors.lastname: Irie
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Okusu
authors.forename: Fumiyo
authors.initials: F
authors.lastname: Kubo
authors.forename: Yozo
authors.initials: Y
authors.lastname: Kanamaru
authors.forename: Ihoko
authors.initials: I
authors.lastname: Nakashoutani
authors.forename: Kazutomi
authors.initials: K
authors.lastname: Yoshiuchi
authors.forename: Ken'ya
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.forename: Iichiro
authors.initials: I
authors.lastname: Shimomura
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kosugi
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000069438:Ezetimibe / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D008055:Lipids; D002784:Cholesterol; D000069438:Ezetimibe